Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
September 29 2023 - 7:05AM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced President and Chief Executive Officer Stephen
Dilly, MBBS, PhD, has been named the winner of the prestigious 2023
Bloom Burton Award. Dr. Dilly was recognized for his leadership of
Vancouver-headquartered Sierra Oncology where he led the company
through Phase 3 clinical development of momelotinib and its drive
toward commercialization up until the company’s $1.9 billion
acquisition by GSK. The compound received approval by the U.S. Food
and Drug Administration on September 15, 2023.
“I am humbled by this unexpected honor, particularly given the
caliber of finalists at this year’s ceremony. This award reaffirms
the importance and impact of a strong team executing on a common
vision,” said Dr. Dilly. “At Codexis, I feel fortunate to be
surrounded by many of the same individuals who were critical to
this success at Sierra, as well as Aimmune Therapeutics. I look
forward to working with this team as we continue to deliver
exquisite enzymes for the betterment of human health.”
Bestowed annually and nominated by the public at large, the
Bloom Burton Award honors an individual who made the greatest
contribution to Canada’s innovative healthcare industry the
previous year. Three finalists and the winner are chosen by an
independent panel of judges consisting of international leaders in
healthcare investment, entrepreneurship and journalism. For more
information, visit www.bloomburton.com/gala.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® technology platform to discover, develop
and enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing and
nucleic acid synthesis. The Company is currently developing its
proprietary ECO Synthesis™ platform to enable the scaled
manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information,
visit https://www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae806bb-f003-408b-8f68-d17276433729
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024